← ANALYST RATINGS · TIPRANKS
Surrozen (SRZN): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $49.33, the highest $54.00, the lowest $40.00. The average is +110.5% from the last price of $23.44.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $26.00 → $25.00−3.8% | Hold | +6.7% | Reiterated | 13.10.26on TipRanks 12:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $26.00 → $25.00−3.8% | Hold | +6.7% | Reiterated | 13.10.26on TipRanks 12:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $26.00 → $25.00−3.8% | Hold | +6.7% | Reiterated | 13.10.26on TipRanks 12:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $24.00 → $25.00+4.2% | Hold | +6.7% | Reiterated | 13.10.26on TipRanks 12:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $26.00 → $25.00−3.8% | Hold | +6.7% | Reiterated | 13.10.26on TipRanks 12:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $26.00 → $24.50−5.8% | Hold | +4.5% | Reiterated | 13.10.26on TipRanks 12:06 | — | |
| Phil Nadeau★★★★★★★★★★#1350 · hits 48% · avg +8.7% | TD Cowen | — | Buy | — | Reiterated | 12.10.26on TipRanks 12:55 | −16.5%next day −5.0% | ↗ |
| Steven Seedhouse★★★★★★★★★★#1374 · hits 43% · avg +10.3% | Cantor Fitzgerald | $40.00 | Buy | +70.6% | Reiterated | 11.10.26on TipRanks Oct 12 08:20 | −16.5%next day −5.0% | ↗ |
| Lachlan Hanbury Brown★★★★★★★★★★#11394 · hits 35% · avg −5.4% | William Blair | — | Buy | — | Reiterated | 02.10.26on TipRanks 10:15 | −3.0%next day −1.3% · 5 days +0.1% | ↗ |
| Patrick Dolezal★★★★★★★★★★#1287 · hits 44% · avg +15.1% | LifeSci Capital | $54.00 | Buy | +130.4% | Assigned | 26.09.26on TipRanks Sep 24 11:35 | +108.5%next day −12.8% · 5 days −10.5% | ↗ |
| Matthew Caufield★★★★★★★★★★#1718 · hits 42% · avg +10.1% | H.C. Wainwright | $44.00 → $54.00+22.7% | Buy | +130.4% | Reiterated | 25.09.26on TipRanks 06:15 | −12.8%next day +1.1% · 5 days −0.5% | ↗ |
| Unknown Analyst | Guggenheim | $42.00 | Buy | +79.2% | Reiterated | 13.08.26on TipRanks Aug 17 13:45 | −2.6%next day +1.2% · 5 days +1.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Surrozen
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $47.50 at a price of $32.18 (+47.6%); now: $47.50 at $23.44 (+102.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 3 | 5 | 7 | 6 |
| Buy | 7 | 4 | 2 | 0 | 0 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.10 (from $-1.47 to $-0.47). Last quarter: $-0.41.
Sales
Next quarter’s sales estimate — $0M (from $0M to $1M). Last quarter: $5M.
Best top-analyst consensus in the sector · Healthcare
About Surrozen
- CEO: Craig C. Parker
- Employees: 44
- 171 Oyster Point Boulevard, South San Francisco, CA, 94080, US
- www.surrozen.com
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Data from the stock’s TipRanks forecast page, read 108 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗